WFA Asset Management Corp Invests $68,000 in Organon & Co. (NYSE:OGN)

WFA Asset Management Corp bought a new position in Organon & Co. (NYSE:OGN) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 4,525 shares of the company’s stock, valued at approximately $68,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Spire Wealth Management increased its stake in Organon & Co. by 39.6% in the 4th quarter. Spire Wealth Management now owns 5,988 shares of the company’s stock worth $89,000 after purchasing an additional 1,700 shares in the last quarter. EMC Capital Management increased its position in shares of Organon & Co. by 343.9% in the fourth quarter. EMC Capital Management now owns 13,831 shares of the company’s stock worth $206,000 after acquiring an additional 10,715 shares in the last quarter. Sippican Capital Advisors raised its holdings in shares of Organon & Co. by 138.7% during the fourth quarter. Sippican Capital Advisors now owns 36,352 shares of the company’s stock valued at $542,000 after acquiring an additional 21,122 shares during the period. Allen Capital Group LLC acquired a new stake in shares of Organon & Co. during the fourth quarter valued at approximately $150,000. Finally, Robeco Institutional Asset Management B.V. purchased a new stake in shares of Organon & Co. in the 4th quarter valued at approximately $2,263,000. 77.43% of the stock is owned by institutional investors and hedge funds.

Organon & Co. Price Performance

Shares of OGN opened at $15.59 on Friday. The business’s 50-day moving average is $15.47 and its 200-day moving average is $17.91. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. The company has a market capitalization of $4.01 billion, a price-to-earnings ratio of 3.09, a P/E/G ratio of 0.89 and a beta of 0.76. Organon & Co. has a fifty-two week low of $13.87 and a fifty-two week high of $23.10.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Thursday, October 31st. The company reported $0.87 EPS for the quarter, missing the consensus estimate of $0.90 by ($0.03). Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. The company had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.56 billion. During the same quarter in the prior year, the firm earned $0.78 earnings per share. The company’s revenue was up 4.1% on a year-over-year basis. Equities research analysts expect that Organon & Co. will post 3.83 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a research report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $21.33.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.